Esco Aster is uniquely positioned in Singapore for the Singapore market at the intersection of animal health and human biotechnology, providing an integrated pathway that enables advanced therapeutic platforms to progress from veterinary commercialization to human clinical development.
Operating from our GLP- and GMP-compliant manufacturing facilities in Singapore, we provide contract development and manufacturing (CDMO) services for advanced therapeutic medicinal products (ATMPs) across both veterinary and human applications. Our capabilities span the entire product lifecycle—from early development and process optimization to GMP manufacturing, clinical development support, veterinary central laboratory services, contract testing, and commercial manufacturing.
Our core differentiation lies in helping biotechnology companies leverage the Singapore veterinary market as a strategic translational platform.
Rather than viewing animal health as a separate commercial opportunity, we enable innovators to validate their technologies in a regulated, revenue-generating market before advancing into human non-clinical and clinical development.
Esco Aster supports technology transfer and development across a broad range of advanced therapeutic modalities, including mesenchymal stromal cells (MSCs), secretomes/conditioned media, exosomes, extracellular vesicles, induced pluripotent stem cells (iPSCs), peptides, single-domain antibodies (nanobodies), monoclonal antibodies, fusion proteins, multispecific antibodies, cell and gene therapies (e.g., NK/CAR-T), and immunotherapies.
Through our Manufacturing Science and Technology (MSAT) capabilities, these products can be efficiently transferred into commercial GMP manufacturing for the Singapore veterinary market.
This “Vet-to-Human” translational model creates multiple value inflection points for biotechnology companies.
Commercialization in veterinary medicine enables developers to:
By combining development, manufacturing, commercialization, and translational expertise within a single organization, Esco Aster reduces technical, regulatory, and operational risk while accelerating the path from laboratory innovation to clinical impact.
Beyond manufacturing, Esco Aster works with strategic investors, public-sector partners, and Enterprise Singapore funding programmes to help companies build capital-efficient development strategies.
Our ability to integrate private investment with government grant support allows innovative platforms to achieve veterinary proof-of-concept and proof-of-platform milestones while preparing for subsequent human therapeutic development.
Our commercial animal health portfolio spans dermatology, oncology, orthopaedics and musculoskeletal disorders, regenerative medicine, wound healing, vascular disease, immunology, and clinical nutrition nutraceuticals/supplements using novel oral dispersible films with our formulation partners.
Our commercial Singapore Food Agency site also produces cell-derived exosomes/extracellular vesicles from mammalian cell, milk, and plant sources, as well as cell-based foods specifically for nutricosmetics, alongside the use of the same ingredients for medical aesthetics through an “inside and out” beauty concept.
We also support pioneering applications such as iPSC-based fertility preservation and assisted reproduction for endangered species, demonstrating the versatility of advanced cell technologies beyond traditional therapeutic indications.
As Singapore continues to establish itself as a global hub for advanced therapeutics, Esco Aster provides a unique translational ecosystem where innovation can move seamlessly from development to veterinary commercialization and ultimately to human therapeutics.
By bridging these traditionally separate markets, we help transform platform technologies into validated products with stronger clinical evidence, commercial traction, and investment readiness.
Contact Esco Aster for collaborations today at [email protected].